Literature DB >> 1662190

Penetration of rufloxacin into human prostatic tissue and fluid.

J B Boerema1, D Bach, C Jol, W Pahlmann.   

Abstract

The penetration of rufloxacin into prostatic tissue and prostatic fluid was investigated in 16 patients undergoing elective transurethral prostate resection. Rufloxacin 400 mg was given orally approximately 16 h before surgery with a further dose of 200 mg approximately 5 h before surgery. Sampling was inadequate in three patients. One patient reported transient flushing and headache after the first dose of rufloxacin and was hence withdrawn from the study. In the remaining 12 evaluable patients, the mean ratios of rufloxacin concentrations (determined by HPLC) in prostatic tissue and fluid to the plasma concentration were 1.9 and 1.5, respectively. There were no significant differences between the tissue penetration ratios in different parts of the prostate. The levels of rufloxacin found in prostate tissue and fluid, in this study, exceeded the MICs for most micro-organisms causing chronic bacterial prostatitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662190     DOI: 10.1093/jac/28.4.547

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

2.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

4.  Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.

Authors:  M Lazzaroni; B P Imbimbo; S Bargiggia; O Sangaletti; L Dal Bo; G Broccali; G Bianchi Porro
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  Pharmacokinetics of rufloxacin in patients with impaired renal function.

Authors:  G Perry; T G Mant; P J Morrison; S Sacks; J Woodcook; R Wise; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections.

Authors:  R Rimoldi; M Fioretti; A Albrici; B P Imbimbo
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.